Databasing for Dollars
Executive SummaryGenome Therapeutics has now signed its third data base deal, virtually completing its metamorphosis from a positional cloner into a data base provider. The new mantra for platform companies: if you create information, sell information. GTC finds selling subscriptions easier and more profitable than selling research deals since the number of potential subscribers is, unlike the number of potential deal partners, virtually unlimited.
You may also be interested in...
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.